For more than 5 decades, the only available treatment for the prevention of atrial fibrillation
(AF)-related stroke were the vitamin K antagonists. Recently, novel oral anticoagulants …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …

The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …

OBJECTIVE To summarize the available evidence on the issues in health economics related
to oral anticoagulation for stroke prevention in atrial fibrillation (AF) in the US. DATA …

Objective To conduct a systematic review of economic models of newer anticoagulants for
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …

Our objective is to summarize the key components of a health economic evaluation of
antithrombotic treatments for stroke prevention in patients with atrial fibrillation (AF). The key …